Aktiesnakken — Februar 2011
-
n biosimilar til avastin
-
De har lavet partnerskab med russerne fordi avastin er for dyr
-
Phase 1 kommer i efteråret
-
Deres mcap er iøvrigt 220 mill
-
De har prækliniske data som viser at de er ligeså effektive som avastin
-
Som omsætter for 5,7 mia!
-
Usd!!
-
Men vi er i præklinik og på vej ibd i fase 1
-
Blokerer vegf2
-
100% humant antistof
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind